Literature DB >> 9607592

Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.

J F Ju1, D Banerjee, H J Lenz, K D Danenberg, T C Schmittgen, C P Spears, A H Schönthal, D J Manno, D Hochhauser, J R Bertino, P V Danenberg.   

Abstract

HL-60 cells that stably express transfected wild-type (wt) p53 were used to determine whether restoration of wt p53 increased the chemosensitivity of cells that normally lack p53 activity. The wt p53 HL-60 transfectants (SN3 cells) were more sensitive than the parental (S) cells to a number of common anticancer drugs representing various mechanisms of action, whereas HL-60 cells transfected with p53 genes mutated at codons 248 and 143 were not sensitized. The sensitization ratio due to the transfected wt p53 varied from about 2-fold for cisplatin to over 50-fold for thymidine. Cells treated with the thymidylate synthase inhibitor 5-fluoro-2'-deoxyuridine (FdUrd) were used to study changes in various p53-associated gene expressions. A higher percentage of apoptotic cells among the SN3 cells was observed than among the S cells at each concentration of FdUrd. The S cells had undetectable levels of bax and high levels of bcl-2, whereas the SN3 cells had undetectable levels of bcl-2 levels and appreciable basal levels of bax. After FdUrd treatment of SN3 cells, both p53 and bax levels increased, but the induction of bax was faster than that of p53 and paralleled the appearance of apoptotic DNA laddering. FdUrd treatment induced p21 expression and increased the G1 fraction of the SN3 cells but did not induce p21 or change the phase distribution in the S cells. FdUrd treatment also induced the expression and phosphorylation of cyclin D1 in the SN3 cells but not in the S cells. These results show that transfected wt p53 confers multidrug sensitivity to HL-60 cells by re-adjustment of the expressions of apoptosis genes and displays other properties characteristic of endogenously originated wt p53.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607592

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  Tumor suppressor p53 status does not determine the differentiation-associated G₁ cell cycle arrest induced in leukemia cells by 1,25-dihydroxyvitamin D₃ and antioxidants.

Authors:  Thelma Thompson; Michael Danilenko; Lyubomir Vassilev; George P Studzinski
Journal:  Cancer Biol Ther       Date:  2010-08-13       Impact factor: 4.742

2.  Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy.

Authors:  C Compagnin; M Mognato; L Celotti; G Canti; G Palumbo; E Reddi
Journal:  Cell Prolif       Date:  2010-06       Impact factor: 6.831

3.  Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity.

Authors:  A Catalano; M Romano; I Robuffo; L Strizzi; A Procopio
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

4.  Recurrent growth factor starvation promotes drug resistance in human leukaemic cells.

Authors:  K Saeki; E Okuma; A Yuo
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

5.  Decrease of ABCB1 protein expression and increase of G1 phase arrest induced by oleanolic acid in human multidrug-resistant cancer cells.

Authors:  Didi Wang; Jincai Wang; Juan Zhang; Xin Yi; Jinhua Piao; Li Li; Jianjie Wang; Pengxia Zhang; Qiyang He
Journal:  Exp Ther Med       Date:  2021-05-09       Impact factor: 2.447

6.  Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.

Authors:  Timothy S Pardee
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

7.  Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.

Authors:  Laura Quotti Tubi; Carmela Gurrieri; Alessandra Brancalion; Laura Bonaldi; Roberta Bertorelle; Sabrina Manni; Laura Pavan; Federica Lessi; Renato Zambello; Livio Trentin; Fausto Adami; Maria Ruzzene; Lorenzo A Pinna; Gianpietro Semenzato; Francesco Piazza
Journal:  J Hematol Oncol       Date:  2013-10-12       Impact factor: 17.388

8.  Mutation of p53 Gene and Its Correlation with the Clinical Outcome in Dogs with Lymphoma.

Authors:  A Koshino; Y Goto-Koshino; A Setoguchi; K Ohno; H Tsujimoto
Journal:  J Vet Intern Med       Date:  2015-12-17       Impact factor: 3.333

Review 9.  Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients.

Authors:  Elise Aasebø; Rakel B Forthun; Frode Berven; Frode Selheim; Maria Hernandez-Valladares
Journal:  Curr Pharm Biotechnol       Date:  2016       Impact factor: 2.837

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.